{"doi":"10.1159/000226800","title":"Mitoxantrone, Etoposide and Cytarabine in the Treatment of Acute Nonlymphocytic Leukemia","abstract":"<jats:p>In a phase I/II study mitoxantrone and etoposide, in combination with cytarabine, were given to 26 patients with refractory, relapsed, and previously untreated acute nonlymphocytic leukemia. Therapy consisted of mitoxantrone 12 mg/m2/day for 3 days, etoposide 100 mg/m2/day and cytarabine 1 g/m2 twice a day for 5 days. A total of 14 complete remissions (CR, 54%) were noted. Among refractory patients 5 of 10 achieved a CR as compared to 5 of 6 in the previously untreated group. A favorable response was also seen in patients with late relapse off treatment (3/4 CR) while patients relapsing on therapy did worse (1/6 CR). The results suggest a high antileukemic activity and a moderate toxicity for this drug combination.</jats:p>","journal":"Oncology","year":2009,"id":632601,"datarank":0.49983067652628066,"base_score":3.332204510175204,"endowment":3.332204510175204,"self_citation_contribution":0.49983067652628066,"citation_network_contribution":0.0,"self_endowment_contribution":0.49983067652628066,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":27,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1639842,"name":"Johanna Björnsdottir","orcid":null,"position":1,"is_corresponding":false},{"id":1363265,"name":"Leif Stenke","orcid":"0000-0002-3554-576X","position":2,"is_corresponding":false},{"id":1639843,"name":"Gunnar Grimfors","orcid":null,"position":3,"is_corresponding":false},{"id":453794,"name":"Magnus Björkholm","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Mitoxantrone, Etoposide and Cytarabine in the Treatment of Acute Nonlymphocytic Leukemia","abstract":"<jats:p>In a phase I/II study mitoxantrone and etoposide, in combination with cytarabine, were given to 26 patients with refractory, relapsed, and previously untreated acute nonlymphocytic leukemia. Therapy consisted of mitoxantrone 12 mg/m2/day for 3 days, etoposide 100 mg/m2/day and cytarabine 1 g/m2 twice a day for 5 days. A total of 14 complete remissions (CR, 54%) were noted. Among refractory patients 5 of 10 achieved a CR as compared to 5 of 6 in the previously untreated group. A favorable response was also seen in patients with late relapse off treatment (3/4 CR) while patients relapsing on therapy did worse (1/6 CR). The results suggest a high antileukemic activity and a moderate toxicity for this drug combination.</jats:p>","is_dataset_classified":null,"base_score":3.332204510175204,"endowment":3.332204510175204,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"2314823","pmcid":null,"openalex_id":"https://openalex.org/W2027869118","authors":[],"funders":[],"total_grants":0,"fwci":0.3331,"citation_percentile":0.61324284,"influential_citations":0,"citation_trend":[{"year":2019,"count":1},{"year":2021,"count":1}],"oa_status":"closed","license":"https://karger.com/pages/terms-and-conditions","oa_locations":[{"url":"https://www.karger.com/Article/Pdf/226800","host_type":"publisher"},{"url":"https://karger.com/article-pdf/doi/10.1159/000226800","host_type":"publisher"},{"url":"https://doi.org/10.1159/000226800","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/2314823","host_type":"repository"}],"fields_of_study":["Acute Myeloid Leukemia Research","Cancer therapeutics and mechanisms","Lung Cancer Research Studies"],"mesh_terms":["Adolescent","Adult","Aged","Antineoplastic Combined Chemotherapy Protocols","Cytarabine","Etoposide","Female","Humans","Male","Middle Aged","Mitoxantrone","Leukemia, Myeloid, Acute"],"keywords":["Mitoxantrone","Etoposide","Cytarabine","Medicine","Internal medicine","Refractory (planetary science)","Chemotherapy","Leukemia","Gastroenterology","Toxicity","Amsacrine","Antimetabolite","Oncology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T10:02:58.567318Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}